Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
28 hedge funds and large institutions have $2.13M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
4% less capital invested
Capital invested by funds: $2.22M → $2.13M (-$90K)
7% less funds holding
Funds holding: 30 → 28 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.4K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.55K |
| 3 |
Renaissance Technologies
New York
|
+$382 |
| 4 |
Citigroup
New York
|
+$159 |
| 5 |
LPL Financial
San Diego,
California
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$95.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$13K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.84K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$6.04K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3K |
BLCM Hedge Fund Activity: Q3 2022 in Review
28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2022, worth a combined $2.13M — down 4.1% from $2.22M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLCM and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4.4K. The largest seller was Ikarian Capital, cutting an estimated $95.9K.
- 28 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2022, down from 30 in Q2 2022.
- Funds reported $2.13M of Bellicum Pharmaceuticals, Inc. stock for Q3 2022, down 4.1% quarter-over-quarter.
- 1 fund opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2022 and 3 closed out, a net change of -2 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $4.4K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2022 was Ikarian Capital, an estimated $95.9K sold.
Based on aggregated 13F filings for Q3 2022.